Gallotannin-rich Caesalpinia spinosa fraction decreases the primary tumor and factors associated with poor prognosis in a murine breast cancer model

BMC Complementary and Alternative Medicine

Volumn 13, Issue , 2013, Pages

  Urueña, Claudia ^a   Mancipe, Juan ^a   Hernandez, John ^a   Castañeda, Diana ^a   Pombo, Luis ^b   Gomez, Alejandra ^a   Asea, Alexzander ^c   Fiorentino, Susana ^a  

^a PONTIFICIA UNIVERSIDAD JAVERIANA   (Colombia)

^b Juan N Corpas University   (Colombia)

^c MOREHOUSE SCHOOL OF MEDICINE   (United States)

Author keywords

4T1; Apoptosis; Breast cancer; Caesalpinia spinosa; IL 6; Metastasis

Indexed keywords

CASPASE 3; CYTOKINE; DNA; DOXORUBICIN; INTERLEUKIN 6; P2ET FRACTION; PHOSPHATIDYLSERINE; PLANT EXTRACT; TANNIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CAESALPINIA; CAESALPINIA SPINOSA; CANCER CELL; CANCER PROGNOSIS; CELL COUNT; CELL LINE; CELL MIGRATION; CLONOGENESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DNA FRAGMENTATION; FEMALE; FLOW CYTOMETRY; FRACTIONATION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; LEUKOCYTE; LEUKOCYTE COUNT; MEDICINAL PLANT; MEMBRANE DEPOLARIZATION; METASTASIS; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; SERUM; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CAESALPINIA; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HYDROLYZABLE TANNINS; INTERLEUKIN-6; MICE; MICE, INBRED BALB C; PLANT EXTRACTS; PROGNOSIS;

EID: 84875657075     PISSN: None     EISSN: 14726882     Source Type: Journal    
DOI: 10.1186/1472-6882-13-74     Document Type: Article

References (43)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90. 10.3322/caac.20107, 21296855.
2. Instituto Nacional de Cancerologia Anuario Estadistico 2009, 2011.: 7, Instituto Nacional de Cancerologia.
3. Ali SM, Harvey HA, Lipton A. Metastatic breast cancer: overview of treatment. Clin Orthop Relat Res 2003, (415 Suppl):S132-S137.
4. Obeid M, Panaretakis T, Tesniere A, Joza N, Tufi R, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Leveraging the immune system during chemotherapy: moving calreticulin to the cell surface converts apoptotic death from " silent" to immunogenic. Cancer Res 2007, 67(17):7941-7944. 10.1158/0008-5472.CAN-07-1622, 17804698.
5. David R. The art of healing in ancient Egypt: a scientific reappraisal. Lancet 2008, 372(9652):1802-1803. 10.1016/S0140-6736(08)61749-3, 19048654.
6. Khanbabaee K, van Ree T. Tannins: classification and definition. Nat Prod Rep 2001, 18(6):641-649.
7. Liao S, Umekita Y, Guo J, Kokontis JM, Hiipakka RA. Growth inhibition and regression of human prostate and breast tumors in athymic mice by tea epigallocatechin gallate. Cancer Lett 1995, 96(2):239-243. 10.1016/0304-3835(95)03948-V, 7585463.
8. Yang LL, Lee CY, Yen KY. Induction of apoptosis by hydrolyzable tannins from Eugenia jambos L. on human leukemia cells. Cancer Lett 2000, 157(1):65-75. 10.1016/S0304-3835(00)00477-8, 10893444.
9. Saleem A, Husheem M, Harkonen P, Pihlaja K. Inhibition of cancer cell growth by crude extract and the phenolics of Terminalia chebula retz. fruit. J Ethnopharmacol 2002, 81(3):327-336. 10.1016/S0378-8741(02)00099-5, 12127233.
10. Ben-Baruch A. Host microenvironment in breast cancer development: inflammatory cells, cytokines and chemokines in breast cancer progression: reciprocal tumor-microenvironment interactions. Breast Cancer Res 2003, 5(1):31-36. 10.1186/bcr690, 154133, 12559043.
11. Salgado R, Junius S, Benoy I, Van Dam P, Vermeulen P, Van Marck E, Huget P, Dirix LY. Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer 2003, 103(5):642-646. 10.1002/ijc.10833, 12494472.
12. Castaneda DM, Pombo LM, Uruena CP, Hernandez JF, Fiorentino S. A gallotannin-rich fraction from Caesalpinia spinosa (Molina) Kuntze displays cytotoxic activity and raises sensitivity to doxorubicin in a leukemia cell line. BMC Complement Altern Med 2012, 12:38. 10.1186/1472-6882-12-38, 3353181, 22490328.
13. Gali-Muhtasib HU, Perchellet JP, Khatib SH. Inhibition of ultraviolet-B radiation induced ornithine decarboxylase activity and edema formation by hydrolyzable and condensed tannins in mouse skin in vivo. Anticancer Res 1997, 17(6D):4507-4513.
14. Gali-Muhtasib HU, Yamout SZ, Sidani MM. Tannins protect against skin tumor promotion induced by ultraviolet-B radiation in hairless mice. Nutr Cancer 2000, 37(1):73-77. 10.1207/S15327914NC3701_9, 10965522.
15. Aslakson CJ, Miller FR. Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992, 52(6):1399-1405.
16. Heppner GH, Miller FR, Shekhar PM. Nontransgenic models of breast cancer. Breast Cancer Res 2000, 2(5):331-334. 10.1186/bcr77, 138654, 11250725.
17. Uruena C, Cifuentes C, Castaneda D, Arango A, Kaur P, Asea A, Fiorentino S. Petiveria alliacea extracts uses multiple mechanisms to inhibit growth of human and mouse tumoral cells. BMC Complement Altern Med 2008, 8:60. 10.1186/1472-6882-8-60, 2613870, 19017389.
18. Du G, Lin H, Wang M, Zhang S, Wu X, Lu L, Ji L, Yu L. Quercetin greatly improved therapeutic index of doxorubicin against 4T1 breast cancer by its opposing effects on HIF-1alpha in tumor and normal cells. Cancer Chemother Pharmacol 2010, 65(2):277-287. 10.1007/s00280-009-1032-7, 19466611.
19. Ji BC, Hsu WH, Yang JS, Hsia TC, Lu CC, Chiang JH, Yang JL, Lin CH, Lin JJ, Suen LJ. Gallic acid induces apoptosis via caspase-3 and mitochondrion-dependent pathways in vitro and suppresses lung xenograft tumor growth in vivo. J Agric Food Chem 2009, 57(16):7596-7604. 10.1021/jf901308p, 20349925.
20. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri ES, Baehrecke EH, Blagosklonny MV, El-Deiry WS, Golstein P, Green DR. Classification of cell death: recommendations of the Nomenclature Committee on Cell Death 2009. Cell Death Differ 2009, 16(1):3-11. 10.1038/cdd.2008.150, 2744427, 18846107.
21. Chen R, Gandhi V, Plunkett W. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia. Cancer Res 2006, 66(22):10959-10966. 10.1158/0008-5472.CAN-06-1216, 17108134.
22. Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 2003, 106(6):879-886. 10.1002/ijc.11337, 12918065.
23. DuPre SA, Hunter KW. Murine mammary carcinoma 4T1 induces a leukemoid reaction with splenomegaly: association with tumor-derived growth factors. Exp Mol Pathol 2007, 82(1):12-24. 10.1016/j.yexmp.2006.06.007, 16919266.
24. Nimieri HS, Makoni SN, Madziwa FH, Nemiary DS. Leukemoid reaction response to chemotherapy and radiotherapy in a patient with cervical carcinoma. Ann Hematol 2003, 82(5):316-317.
25. Schniewind B, Christgen M, Hauschild A, Kurdow R, Kalthoff H, Klomp HJ. Paraneoplastic leukemoid reaction and rapid progression in a patient with malignant melanoma: establishment of KT293, a novel G-CSF-secreting melanoma cell line. Cancer Biol Ther 2005, 4(1):23-27. 10.4161/cbt.4.1.1447, 15662134.
26. Witz IP. The tumour microenvironment-introduction. Semin Cancer Biol 2002, 12(2):87-88. 10.1006/scbi.2001.0415, 12027579.
27. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol 1990, 8:253-278. 10.1146/annurev.iy.08.040190.001345, 2188664.
28. Nishimura R, Nagao K, Miyayama H, Matsuda M, Baba K, Matsuoka Y, Yamashita H, Fukuda M, Mizumoto T, Hamamoto R. An analysis of serum interleukin-6 levels to predict benefits of medroxyprogesterone acetate in advanced or recurrent breast cancer. Oncology 2000, 59(2):166-173. 10.1159/000012155, 10971177.
29. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev 2001, 15(22):2922-2933.
30. Chang HY, Yang X. Proteases for cell suicide: functions and regulation of caspases. Microbiol Mol Biol Rev 2000, 64(4):821-846. 10.1128/MMBR.64.4.821-846.2000, 99015, 11104820.
31. Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev 1999, 13(15):1899-1911. 10.1101/gad.13.15.1899, 10444588.
32. Locatelli C, Rosso R, Santos-Silva MC, de Souza CA, Licinio MA, Leal P, Bazzo ML, Yunes RA, Creczynski-Pasa TB. Ester derivatives of gallic acid with potential toxicity toward L1210 leukemia cells. Bioorg Med Chem 2008, 16(7):3791-3799. 10.1016/j.bmc.2008.01.049, 18295493.
33. Chen WJ, Chang CY, Lin JK. Induction of G1 phase arrest in MCF human breast cancer cells by pentagalloylglucose through the down-regulation of CDK4 and CDK2 activities and up-regulation of the CDK inhibitors p27(Kip) and p21(Cip). Biochem Pharmacol 2003, 65(11):1777-1785. 10.1016/S0006-2952(03)00156-4, 12781329.
34. Hua KT, Way TD, Lin JK. Pentagalloylglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates ErbB/PI3K/Akt pathway in human breast cancer MCF-7 cells. Mol Carcinog 2006, 45(8):551-560. 10.1002/mc.20226, 16637063.
35. Baliga MS, Meleth S, Katiyar SK. Growth inhibitory and antimetastatic effect of green tea polyphenols on metastasis-specific mouse mammary carcinoma 4T1 cells in vitro and in vivo systems. Clin Cancer Res 2005, 11(5):1918-1927. 10.1158/1078-0432.CCR-04-1976, 15756018.
36. Lirdprapamongkol K, Sakurai H, Kawasaki N, Choo MK, Saitoh Y, Aozuka Y, Singhirunnusorn P, Ruchirawat S, Svasti J, Saiki I. Vanillin suppresses in vitro invasion and in vivo metastasis of mouse breast cancer cells. Eur J Pharm Sci 2005, 25(1):57-65. 10.1016/j.ejps.2005.01.015, 15854801.
37. Chiu JJ, Sgagias MK, Cowan KH. Interleukin 6 acts as a paracrine growth factor in human mammary carcinoma cell lines. Clin Cancer Res 1996, 2(1):215-221.
38. Danforth DN, Sgagias MK. Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 1993, 53(7):1538-1545.
39. Krueger J, Ray A, Tamm I, Sehgal PB. Expression and function of interleukin-6 in epithelial cells. J Cell Biochem 1991, 45(4):327-334. 10.1002/jcb.240450404, 2045425.
40. Conze D, Weiss L, Regen PS, Bhushan A, Weaver D, Johnson P, Rincon M. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001, 61(24):8851-8858.
41. Ara T, Declerck YA. Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer 2010, 46(7):1223-1231. 10.1016/j.ejca.2010.02.026, 2917917, 20335016.
42. Ravishankaran P, Karunanithi R. Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 2011, 9:18. 10.1186/1477-7819-9-18, 3045973, 21294915.
43. Pulaski BA, Ostrand-Rosenberg S. Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998, 58(7):1486-1493.